STOCK TITAN

[Form 4] Tivic Health Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Christina Rizopoulos, a director of Tivic Health Systems, Inc. (TIVC), was granted a stock option to purchase 7,500 shares of common stock with an exercise price of $3.32 per share, recorded with a transaction date of 08/06/2025. The filing shows 7,500 derivative securities beneficially owned following the grant.

The option vests in a series of four successive equal quarterly installments, rounded downward to the nearest whole share, such that the award is 100% vested upon the first anniversary of the grant date, and the option carries an expiration date of 08/05/2035. The grant ties director compensation to future share performance while establishing a roughly ten-year exercise window.

Christina Rizopoulos, amministratrice di Tivic Health Systems, Inc. (TIVC), ha ricevuto un'opzione per acquistare 7,500 azioni ordinarie al prezzo di esercizio di $3.32 per azione, con data di transazione registrata 08/06/2025. La comunicazione indica che dopo la concessione risultano di sua proprietà beneficiaria 7,500 strumenti derivati.

L'opzione matura in quattro rate trimestrali uguali, arrotondate per difetto alla singola azione, in modo che l'assegnazione sia 100% acquisita al primo anniversario della data di concessione, e l'opzione ha data di scadenza 08/05/2035. La concessione collega la retribuzione del membro del consiglio alla futura performance del titolo, stabilendo al contempo una finestra di esercizio di circa dieci anni.

Christina Rizopoulos, directora de Tivic Health Systems, Inc. (TIVC), recibió una opción para comprar 7,500 acciones ordinarias con un precio de ejercicio de $3.32 por acción, registrada con fecha de transacción 08/06/2025. La presentación indica que tras la concesión posee a título beneficiario 7,500 valores derivados.

La opción se consolida en una serie de cuatro cuotas trimestrales iguales, redondeadas hacia abajo a la acción entera más próxima, de modo que la adjudicación queda 100% consolidada al primer aniversario de la fecha de concesión, y la opción expira el 08/05/2035. La concesión vincula la compensación de la directora al rendimiento futuro de la acción, estableciendo a la vez una ventana de ejercicio de aproximadamente diez años.

Christina Rizopoulos는 Tivic Health Systems, Inc. (TIVC)의 이사로서 1주당 $3.32의 행사가로 보통주 7,500주를 매수할 수 있는 주식옵션을 부여받았으며, 거래일자는 08/06/2025로 기재되어 있습니다. 신고서에는 부여 후 해당 파생증권 7,500주를 실질적으로 보유하고 있는 것으로 표시되어 있습니다.

해당 옵션은 네 번의 동일한 분기별 할부로 베스팅되며, 주수는 내림 처리되어 부여일의 첫 번째 기념일에 100% 권리가 확정되고, 옵션의 만료일은 08/05/2035입니다. 이 부여는 임원의 보수를 향후 주가 성과에 연동시키는 동시에 약 10년의 행사 기간을 설정합니다.

Christina Rizopoulos, administratrice de Tivic Health Systems, Inc. (TIVC), s'est vu accorder une option d'achat de 7,500 actions ordinaires au prix d'exercice de $3.32 par action, enregistrée avec une date de transaction 08/06/2025. Le dépôt indique que 7,500 titres dérivés lui sont détenus à titre bénéficiaire après l'attribution.

L'option s'acquiert par une série de quatre versements trimestriels égaux, arrondis à l'inférieur à l'action entière la plus proche, de sorte que l'attribution est 100% acquise au premier anniversaire de la date d'attribution, et l'option porte une date d'expiration au 08/05/2035. Cette attribution lie la rémunération de l'administratrice à la performance future de l'action tout en établissant une fenêtre d'exercice d'environ dix ans.

Christina Rizopoulos, Mitglied des Vorstands von Tivic Health Systems, Inc. (TIVC), erhielt eine Option zum Erwerb von 7,500 Stammaktien zu einem Ausübungspreis von $3.32 je Aktie, mit im Register vermerktem Transaktionsdatum 08/06/2025. Die Meldung zeigt, dass nach der Gewährung 7,500 derivative Wertpapiere wirtschaftlich in ihrem Besitz sind.

Die Option vestet in vier aufeinanderfolgenden gleichen Quartalsraten, abgerundet auf die nächstniedrigere ganze Aktie, sodass die Zuteilung am ersten Jahrestag des Gewährungsdatums zu 100% erworben ist, und die Option hat ein Ablaufdatum 08/05/2035. Die Gewährung koppelt die Vergütung des Direktors an die künftige Kursentwicklung und stellt gleichzeitig ein rund zehnjähriges Ausübungsfenster bereit.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Director awarded 7,500 options with quarterly vesting to align incentives; disclosure is routine and non-controversial.

The Form 4 documents a standard equity award to a board member rather than a cash payment or change in board composition. The grant details—7,500 options at a $3.32 exercise price, four equal quarterly vesting installments and full vesting at one year—indicate a retention and incentive structure. From a governance perspective, this is a commonplace mechanism to align long-term director interests with shareholders. The filing does not disclose broader plan limits or total dilution, so overall governance impact is limited to this isolated award.

TL;DR: Option grant gives director upside exposure; transaction size and financial impact are not determinable from this filing alone.

This Form 4 reports a derivative grant that creates potential future equity issuance if exercised. Key quantifiable elements are 7,500 options, $3.32 exercise price, vesting over four quarterly installments with full vesting at one year, and an expiration of 08/05/2035. The document does not provide company-wide share counts, plan reserve information, or immediate cash flow effects, so the materiality for shareholders cannot be assessed from this filing alone. As reported, the item is informational and routine rather than materially market-moving.

Christina Rizopoulos, amministratrice di Tivic Health Systems, Inc. (TIVC), ha ricevuto un'opzione per acquistare 7,500 azioni ordinarie al prezzo di esercizio di $3.32 per azione, con data di transazione registrata 08/06/2025. La comunicazione indica che dopo la concessione risultano di sua proprietà beneficiaria 7,500 strumenti derivati.

L'opzione matura in quattro rate trimestrali uguali, arrotondate per difetto alla singola azione, in modo che l'assegnazione sia 100% acquisita al primo anniversario della data di concessione, e l'opzione ha data di scadenza 08/05/2035. La concessione collega la retribuzione del membro del consiglio alla futura performance del titolo, stabilendo al contempo una finestra di esercizio di circa dieci anni.

Christina Rizopoulos, directora de Tivic Health Systems, Inc. (TIVC), recibió una opción para comprar 7,500 acciones ordinarias con un precio de ejercicio de $3.32 por acción, registrada con fecha de transacción 08/06/2025. La presentación indica que tras la concesión posee a título beneficiario 7,500 valores derivados.

La opción se consolida en una serie de cuatro cuotas trimestrales iguales, redondeadas hacia abajo a la acción entera más próxima, de modo que la adjudicación queda 100% consolidada al primer aniversario de la fecha de concesión, y la opción expira el 08/05/2035. La concesión vincula la compensación de la directora al rendimiento futuro de la acción, estableciendo a la vez una ventana de ejercicio de aproximadamente diez años.

Christina Rizopoulos는 Tivic Health Systems, Inc. (TIVC)의 이사로서 1주당 $3.32의 행사가로 보통주 7,500주를 매수할 수 있는 주식옵션을 부여받았으며, 거래일자는 08/06/2025로 기재되어 있습니다. 신고서에는 부여 후 해당 파생증권 7,500주를 실질적으로 보유하고 있는 것으로 표시되어 있습니다.

해당 옵션은 네 번의 동일한 분기별 할부로 베스팅되며, 주수는 내림 처리되어 부여일의 첫 번째 기념일에 100% 권리가 확정되고, 옵션의 만료일은 08/05/2035입니다. 이 부여는 임원의 보수를 향후 주가 성과에 연동시키는 동시에 약 10년의 행사 기간을 설정합니다.

Christina Rizopoulos, administratrice de Tivic Health Systems, Inc. (TIVC), s'est vu accorder une option d'achat de 7,500 actions ordinaires au prix d'exercice de $3.32 par action, enregistrée avec une date de transaction 08/06/2025. Le dépôt indique que 7,500 titres dérivés lui sont détenus à titre bénéficiaire après l'attribution.

L'option s'acquiert par une série de quatre versements trimestriels égaux, arrondis à l'inférieur à l'action entière la plus proche, de sorte que l'attribution est 100% acquise au premier anniversaire de la date d'attribution, et l'option porte une date d'expiration au 08/05/2035. Cette attribution lie la rémunération de l'administratrice à la performance future de l'action tout en établissant une fenêtre d'exercice d'environ dix ans.

Christina Rizopoulos, Mitglied des Vorstands von Tivic Health Systems, Inc. (TIVC), erhielt eine Option zum Erwerb von 7,500 Stammaktien zu einem Ausübungspreis von $3.32 je Aktie, mit im Register vermerktem Transaktionsdatum 08/06/2025. Die Meldung zeigt, dass nach der Gewährung 7,500 derivative Wertpapiere wirtschaftlich in ihrem Besitz sind.

Die Option vestet in vier aufeinanderfolgenden gleichen Quartalsraten, abgerundet auf die nächstniedrigere ganze Aktie, sodass die Zuteilung am ersten Jahrestag des Gewährungsdatums zu 100% erworben ist, und die Option hat ein Ablaufdatum 08/05/2035. Die Gewährung koppelt die Vergütung des Direktors an die künftige Kursentwicklung und stellt gleichzeitig ein rund zehnjähriges Ausübungsfenster bereit.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Valauri Christina Rizopoulos

(Last) (First) (Middle)
47685 LAKEVIEW BOULEVARD

(Street)
FREMONT CA 94538

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tivic Health Systems, Inc. [ TIVC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Purchase) $3.32 08/06/2025 A 7,500 (1) 08/05/2035 Common Stock 7,500 $0.00 7,500 D
Explanation of Responses:
1. The stock option vests in a series of four (4) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the grant date, such that 100% of the stock option will be vested upon the first anniversary of the grant date.
/s/ Jennifer Ernst, attorney-in-fact 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction was reported on the TIVC Form 4?

The Form 4 reports a grant of 7,500 stock options to director Christina Rizopoulos with a transaction date of 08/06/2025.

What is the exercise price for the options reported for TIVC?

The options have an exercise (conversion) price of $3.32 per share.

How do the granted TIVC options vest?

The options vest in a series of four successive equal quarterly installments, rounded downward to the nearest whole share, with 100% vesting upon the first anniversary of the grant date.

When do the TIVC options expire?

The filing lists an expiration date of 08/05/2035 for the reported option award.

How many derivative securities does the reporting person beneficially own after the transaction?

The Form indicates the reporting person beneficially owns 7,500 derivative securities following the reported transaction.
Tivic Health Systems Inc

NASDAQ:TIVC

TIVC Rankings

TIVC Latest News

TIVC Latest SEC Filings

TIVC Stock Data

3.45M
765.79k
10.81%
0%
2.64%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
FREMONT